AMAG Pharmaceuticals Discovers the Cure for Password Woes
Today, AMAG Pharmaceuticals and its Feraheme® treatment, introduced in 2009, has significantly improved the wellbeing of a growing number of patients with iron deficiency anemia. The Lexington, Massachusetts-based biopharmaceutical company develops and commercializes a therapeutic iron compound used in Feraheme and other treatments, as well as novel imaging agents that aid in the diagnosis of cancer and cardiovascular disease. The success of Feraheme has driven new growth at AMAG as the company scales up to meet high demands. Its workforce has more than tripled to approximately 300 people, including a nationwide mobile sales force, and operations have expanded to two Greater Boston facilities.